Do the National Institute of Clinical Excellence guidelines apply to 'real world' use of Abciximab in percutaneous coronary intervention in a teaching hospital setting?
Khan
J M
JM
Watson
R D S
RD
Varma
C
C
Millane
T
T
Lip
G Y H
GY
D000077284:Abciximab; D015906:Angioplasty, Balloon, Coronary / Q000592:standards*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D015331:Cohort Studies; D003327:Coronary Disease / Q000601:surgery*; D005260:Female; D006784:Hospitals, Teaching; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic / Q000592:standards*; D012307:Risk Factors
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D000077284:Abciximab